Archive
Proactive headlines: e-therapeutics, ZAIM Credit Systems, I3 Energy…
A look at some of today's major headlines from the Proactive newswire
Company
e-Therapeutics PLC
LON:ETX
e-Therapeutics PLC is integrating computational power and biology to accelerate the discovery of life-transforming RNAi medicines. The company has developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology to fully capture and interrogate human disease complexity. e-Therapeutics' multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support.
153 stories · page 2 of 8
E-therapeutics triggers Galapagos milestone payment
Signed just over a year ago, the objective of the agreement is to find a new drug approach to idiopathic pulmonary fibrosis “and other fibrotic indications”
E-therapeutics appoints head of intellectual property
Alison Gallafent brings with her 20 years of experience as a patent lawyer
Archive
Proactive news headlines: Alpha Financial Markets, Induction Healthcare, Grow Group, Emmerson...
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news headlines: Mailbox REIT, Momentum Multi-Asset Value, CentralNic, SourceBio International...
A glance at some of the day's highlights from the Proactive Investor's newswire
e-Therapeutics raises £22.5mln in equity raise as it aims to expand RNAi capabilities
"I am excited by the potential of e-Therapeutics' proprietary platform technologies to meaningfully transform and accelerate the drug discovery process," said Ali Mortazavi
E-therapeutics aims for more deals and collaborations after expansion into RNAi
“We have begun to build momentum as we move forward with our strategy delivering scientific progress as well as current and prospective partnerships,” said boss Ali Mortazavi
e-therapeutics reaches two key milestones in Galapagos collaboration
“The progress made to date in our collaboration with Galapagos to discover novel therapeutics in IPF and fibrosis is yet another validation of our technology platform," said chief executive Ali Mortazavi
E-therapeutics appoints pharma veteran as CFO
Since 2009, Karl Keegan has held senior executive roles in private and public companies
e-Therapeutics splits chief executive and executive chairman roles
New chairman Trevor Jones was R&D director of The Wellcome Foundation from 1987 to 1994, and a director of Allergan from 2005 to 2015
e-therapeutics seeks patent for liver gene silencing technology
“Our platform has the significant and added advantage of being able to leverage our expertise in network biology," said chairman Ali Mortazavi
e-Therapeutics unveils results of testing of compounds for potential coronavirus treatment
The company said testing from its network-driven drug discovery platform has revealed that inhibition of the same target, GRP94, is effective at suppressing hyperinflammation and also disrupting the ability of the COVID-19 virus to replicat
e-Therapeutics files more patents for its gene silencing technology
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
e-therapeutics re-energised as executive chairman Mortazavi takes over CEO duties
"Since his appointment in February, Ali has re-energised the company and, importantly, played a significant role in restructuring the portfolio," said non-executive director, Professor Trevor Jones
e-Therapeutics expands scientific advisory board
The biopharmaceutical firm has appointed Bill Harte, chief translational officer at the Case Western Reserve University School of Medicine in Ohio, and John Mattick, a professor of RNA Biology at UNSW Sydney in Australia
e-Therapeutics unveils fundraising plans to enable next stage of growth
The company is aiming to raise the cash through a combination of a placing, a subscription and a retail offer to investors
e-therapeutics teams up with Belgian life sciences giant Galapagos to tackle fibrosis
The work, which will lean into ETX’s expertise in network biology and in silico phenotypic screening, will focus on approaches to modulate one specific mechanism involved in IPF and other fibrotic conditions
e-therapeutics plotting move into RNA interference; appoints industry big hitter to head scientific advisory board
The R&D specialist believes its computational approach to drug discovery could aid the search for new RNAi drug candidates
e-Therapeutics surges as it begins experimental testing of coronavirus treatment compounds
The firm believes the initial compound set has the potential to address both viral replication and the associated excessive immune response caused by the pathogen
e-therapeutics appoints former Silence Therapeutics executive as its chief business officer
Dr Laura Roca-Alonso held positions of increasing responsibility at Silence Therapeutics until 2019, culminating in her role as VP, Head of Corporate Development